08-11-2024, 08:38 PM
Frxb GoCardless raises $75M Series E for its recurring payments network and heads to America
Hey, hey, hey! It s going to be a busy week for the TC crew this week. We re excited about the Apple event, and Y Combinator has its demo day. Alex welcomes you to YC and Apple week on the Equity podcast, and your trusty Daily Crunch team is poised at our laptops air max 96 to share the cream of the news-crop with you!Stay tuned, it s going to be a wild one!聽 鈥?Christine and HajeThe TechCrunch Top 32Dh1 ..Spth!Lmng: Bitwarden s ability to generate hard-to-guess passwords has made it attractive to investors who just pumped $100 million of new funding into the company, which aims to rid the world of people using the same passwords a air max 1 cross their personal and business lives, Paul writes. Wild West of climate tech: Mike has a story about Ceezer closing on 鈧?.2 million to figure out a better way for businesses to carbon-offset.DAO makes us proud: Gaming guild Metaverse Magna is now valued at $30 million after raising $3.2 million in a rec nike air max mens ent round. Tage writes the company plans to build Africa s large Mfpu US charges California man over Shopify data breach
Those numbers aren ;t as impressive as the reported salomon sommerschuhe figures for the Moderna and Pfizer/BioNTech vaccines that are already being distributed via emergency FDA approval, both of which reported 90+% efficacy. But Johnson & Johnson vaccine is a single shot rather than a tw crocs schneestiefel o-course treatment, which should make it much easier to distribute much more quickly. The vaccine also showed 100% efficacy in preventing hospitalization or death among participants in the trial, 28 days after vaccination, which is a key measure when considering the broader impact of COVID-19 on healthcare resources. Efficacy varied by region, with the jab proving 72% effective in the salomon U.S. across moderate and severe cases versus 66% globally.It also important to note that Johnson & Johnson Phase 3 trial is happening amid the emergence of new strains of the virus, including much more contagious versions like the U.K. and South African variants. At the time that both Moderna and BioNTech
Hey, hey, hey! It s going to be a busy week for the TC crew this week. We re excited about the Apple event, and Y Combinator has its demo day. Alex welcomes you to YC and Apple week on the Equity podcast, and your trusty Daily Crunch team is poised at our laptops air max 96 to share the cream of the news-crop with you!Stay tuned, it s going to be a wild one!聽 鈥?Christine and HajeThe TechCrunch Top 32Dh1 ..Spth!Lmng: Bitwarden s ability to generate hard-to-guess passwords has made it attractive to investors who just pumped $100 million of new funding into the company, which aims to rid the world of people using the same passwords a air max 1 cross their personal and business lives, Paul writes. Wild West of climate tech: Mike has a story about Ceezer closing on 鈧?.2 million to figure out a better way for businesses to carbon-offset.DAO makes us proud: Gaming guild Metaverse Magna is now valued at $30 million after raising $3.2 million in a rec nike air max mens ent round. Tage writes the company plans to build Africa s large Mfpu US charges California man over Shopify data breach
Those numbers aren ;t as impressive as the reported salomon sommerschuhe figures for the Moderna and Pfizer/BioNTech vaccines that are already being distributed via emergency FDA approval, both of which reported 90+% efficacy. But Johnson & Johnson vaccine is a single shot rather than a tw crocs schneestiefel o-course treatment, which should make it much easier to distribute much more quickly. The vaccine also showed 100% efficacy in preventing hospitalization or death among participants in the trial, 28 days after vaccination, which is a key measure when considering the broader impact of COVID-19 on healthcare resources. Efficacy varied by region, with the jab proving 72% effective in the salomon U.S. across moderate and severe cases versus 66% globally.It also important to note that Johnson & Johnson Phase 3 trial is happening amid the emergence of new strains of the virus, including much more contagious versions like the U.K. and South African variants. At the time that both Moderna and BioNTech